Лекарственное повреждение печени и вероятность гепатоцеллюлярного рака на фоне химиотерапии колоректального рака (метаанализ)

Опухолевые заболевания — одна из ведущих причин смерти в мире. Неоадъювантная и адъювантная химиотерапии потенциально могут вести к лекарственному поражению печени и карциноме. По данным обзора литературы и метаанализа, средняя взвешенная частота лекарственных повреждений печени для всех препаратов среди пациентов, получающих неоадъювантную химиотерапию по поводу колоректального рака с метастазами в печень, равна 63,2 %. Средняя взвешенная частота тяжелых поражений печени равна 37,2 %. Однако нами не было обнаружено клинических сообщений о формировании карциномы печени вследствие проведения химиотерапии. В настоящее время мы можем сказать, что, несмотря на теоретическую возможность, прием химиотерапии при колоректальном раке не сопровождается развитием гепатоцеллюлярной карциномы.

1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca A Cancer Journal for Clinicians. 2021;71(3):209–49. DOI: 10.3322/caac.21660

2. Björnsson E.S., Stephens C., Atallah E., Robles-Diaz M., Alvarez-Alvarez I., Gerbes A., et al. A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry. Liver Int. 2023;43(1):115–26. DOI: 10.1111/liv.15378

3. Han J., Liu J., Yu Z., Huang R., Zhao L., Xu Y., et al. Risk factors for irinotecan-induced liver injury: A retrospective multicentre cross-sectional study in China. BMJ open. 2023;13(6):e069794. DOI: 10.1136/bmjopen-2022-069794

4. Zeien J., Qiu W., Triay M., Dhaibar H.A., Cruz-Topete D., Cornett E.M., et al. Clinical implications of chemotherapeutic agent organ toxicity on perioperative care. Biomed Pharmacother. 2022;146:112503. DOI: 10.1016/j.biopha.2021.112503

5. Arjmand A., Tsipouras M.G., Tzallas A.T., Forlano R., Manousou P., Giannakeas N. Quantification of liver fibrosis — A comparative study. Applied Sciences. 2020;10(2):447. DOI: 10.3390/app10020447

6. Narita M., Oussoultzoglou E., Chenard M.P., Fuchshuber P., Rather M., Rosso E., et al. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization. Ann Surg Oncol. 2012;19(7):2230–7. DOI: 10.1245/s10434-011-2112-6

7. Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Rev Panam Salud Publica. 2022;46:e112. DOI: 10.26633/rpsp.2022.112

8. Saracoglu I., Akin E., Aydin Dincer G.B. Efficacy of adding pain neuroscience education to a multimodal treatment in fibromyalgia: A systematic review and meta-analysis. Int J Rheum Dis. 2022;25(4):394–404. DOI: 10.1111/1756-185X.14293

9. Zhang Y., Huang L., Wang D., Ren P., Hong Q., Kang D. The ROBINS-I and the NOS had similar reliability but differed in applicability: A random sampling observational studies of systematic reviews/meta-analysis. J Evid Based Med. 2021;14(2):112–22. DOI: 10.1111/jebm.12427

10. Luchini C., Veronese N., Nottegar A., Shin J.I., Gentile G., Granziol U., et al. Assessing the quality of studies in meta-research: Review/guidelines on the most important quality assessment tools. Pharm Stat. 2021;20(1):185–95. DOI: 10.1002/pst.2068

11. Soubrane O., Brouquet A., Zalinski S., Terris B., Brézault C., Mallet V., et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: Correlation with post-hepatectomy outcome. Ann Surg. 2010;251(3):454–60. DOI: 10.1097/SLA.0b013e3181c79403

12. Mehta N.N., Ravikumar R., Coldham C.A., Buckels J.A.C., Hubscher S.G., Bramhall S.R., et al. Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol. 2008;34(7):782–6. DOI: 10.1016/j.ejso.2007.09.007

13. Rubbia-Brandt L., Lauwers G.Y., Wang H., Majno P.E., Tanabe K., X Zhu A. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010;56(4):430–9. DOI: 10.1111/j.1365-2559.2010.03511.x

14. Nordlinger B., Benoist S., Penna C. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;244(5):835.

15. Narita M., Oussoultzoglou E., Jaeck D. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18(Suppl. 3):S310. DOI: 10.1245/s10434-011-1936-4

16. Viganò L., Capussotti L., De Rosa G., De Saussure W.O., Mentha G., Rubbia-Brandt L. Liver resection for colorectal metastases after chemotherapy: Impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg. 2013;258(5):731–42. DOI: 10.1097/SLA.0b013e-3182a6183e

17. Miura K., Nakano H., Sakurai J., Kobayashi S., Koizumi S., Arai T., et al. Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy. Int J Clin Oncol. 2011;16(3):257–63. DOI: 10.1007/s10147-010-0176-0

18. Karoui M., Penna C., Amin-Hashem M., Mitry E., Benoist S., Franc B., et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243(1):1–7. DOI: 10.1097/01.sla.0000193603.26265.c3

19. Tamandl D., Klinger M., Eipeldauer S., Herberger B., Kaczirek K., Gruenberger B., et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18(2):421–30. DOI: 10.1245/s10434-010-1317-4

20. Галимова С.Ф. Лекарственные поражения печени (Часть 1-я). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2012;22(3):38–48.

21. Real M., Barnhill M.S., Higley C., Rosenberg J., Lewis J.H. Drug-induced liver injury: Highlights of the recent literature. Drug Safety. 2019;42(3):365–87. DOI: 10.1007/s40264-018-0743-2

22. Sun Y.K., Zhang Y.F., Xie L., Rong F., Zhu X.Y., Xie J., et al. Progress in the treatment of drug-induced liver injury with natural products. Pharmacol Res. 2022;183:106361. DOI: 10.1016/j.phrs.2022.106361

23. Garcia-Cortes M., Robles-Diaz M., Stephens C., Ortega-Alonso A., Lucena M.I., Andrade R.J. Drug induced liver injury: An update. Arch Toxicol. 2020;94(10):3381–407. DOI: 10.1007/s00204-020-02885-1

24. Li X., Tang J., Mao Y. Incidence and risk factors of drug-induced liver injury. Liver Int. 2022;42(9):1999–2014. DOI: 10.1111/liv.15262

25. Björnsson H.K., Björnsson E.S. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med. 2022;97:26–31. DOI: 10.1016/j.ejim.2021.10.035

26. Andrade R.J., Chalasani N., Björnsson E.S., Suzuki A., Kullak-Ublick G.A., Watkins P.B., et al. Druginduced liver injury. Nat Rev Dis Primers. 2019;5(1):58. DOI: 10.1038/s41572-019-0105-0

27. Strobach D., Benesic A. Drug-induced liver injury. Krankenhauspharmazie. 2023;44(1):3–9.

28. Ragab M., Schlichting H., Hicken M., Mester P., Hirose M., Almeida L.N., et al. Azathioprine promotes intestinal epithelial cell differentiation into Paneth cells and alleviates ileal Crohn’s disease severity. Sci Rep. 2024;14(1):12879. DOI: 10.1038/s41598-024-63730-4

29. Shojaie L., Iorga A., Dara L. Cell death in liver diseases: A review. Int J Mol Sci. 2020;21(24):9682. DOI: 10.3390/ijms21249682

30. Weber S., Gerbes A.L. Challenges and future of drug-induced liver injury research — Laboratory tests. Int J Mol Sci. 2022;23(11):6049. DOI: 10.3390/ijms23116049

31. Devarbhavi H., Aithal G., Treeprasertsuk S., Takikawa H., Mao Y., Shasthry S.M.; Asia Pacific Association of Study of Liver. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int. 2020;15(2):258–82. DOI: 10.1007/s12072-021-10144-3

32. Gijbels E., Vilas-Boas V., Deferm N., Devisscher L., Jaeschke H., Annaert P., et al. Mechanisms and in vitro models of drug-induced cholestasis. Arch Toxicol. 2019;93(5):1169–86. DOI: 10.1007/s00204-019-02437-2

33. Hwang D.B., Seo Y., Lee E., Won D.H., Kim C., Kang M.H., et al. Diagnostic potential of serum miR-532-3p as a circulating biomarker for experimental intrinsic drug-induced liver injury by acetaminophen and cisplatin in rats. Food Chem Toxicol. 2023;178:113890. DOI: 10.1016/j.fct.2023.113890

34. Chen R., Li W., Li R., Ai S., Zhu H., Lin W. Cysteine-activated fluorescence/photoacoustic integrated probe for non-invasive diagnosis of drug-induced liver injury. Chinese Chemical Letters. 2023;34(5):107845. DOI: 10.1016/j.cclet.2022.107845

35. Ramachandran R., Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol. 2009;62(6):481–92. DOI: 10.1136/jcp.2008.058248

36. Ивашкин В.Т., Райхельсон К.Л., Пальгова Л.К., Маевская М.В., Герасимова О.А., Кондрашина Э.А. и др. Лекарственные поражения печени у онкологических пациентов. Онкогематология. 2020;15(3):80–94. DOI: 10.17650/1818-8346-2020-15-3-80-94

37. Yang X.Q., Ye J., Li X., Li Q., Song Y. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes. World J Gastroenterol. 2019;25(28):3753–63. DOI: 10.3748/wjg.v25.i28.3753

38. Corbacioglu S., Jabbour E.J., Mohty M. Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant. 2019;25(7):1271–80. DOI: 10.1016/j.bbmt.2019.02.018

39. Weiss B.M., Sawinski D. Sinusoidal obstruction syndrome. Onco-Nephrology E-Book. 2019;40(4):99–106.e4.

40. Nakano H., Oussoultzoglou E., Rosso E., Casnedi S., Chenard-Neu M.P., Dufour P., et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247(1):118–24. DOI: 10.1097/SLA.0b013e31815774de

41. Zhu C., Ren X., Liu D., Zhang C. Oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Toxicology. 2021;460:152882. DOI: 10.1016/j.tox.2021.152882

42. Teng Y.X., Xie S., Guo P.P., Deng Z.J., Zhang Z.Y., Gao W., et al. Hepatocellular carcinoma in non-alcoholic fatty liver disease: Current progresses and challenges. J Clin Transl Hepatol. 2022;10(5):955–64. DOI: 10.14218/JCTH.2021.00586

43. Chidambaranathan-Reghupaty S., Fisher P.B., Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61. DOI: 10.1016/bs.acr.2020.10.001

44. Müller M., Bird T.G., Nault J.C. The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. J Hepatol. 2020;72(5):990–1002. DOI: 10.1016/j.jhep.2020.01.019

45. Семендяева М.И., Меркулов И.А., Пастухов А.И., Гайдашева Е.В., Лесняк В.Н., Шутова О.В. Гепатоцеллюлярная карцинома — день сегодняшний. Клиническая практика. 2013;2(14):35–49.

46. Wang W., Gao W., Zhu Q., Alasbahi A., Seki E., Yang L. TAK1: A molecular link between liver inflammation, fibrosis, steatosis, and carcinogenesis. Front Cell Dev Biol. 2021;9:734749. DOI: 10.3389/fcell.2021.734749

47. Dhar D., Baglieri J., Kisseleva T., Brenner D.A. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (Maywood). 2020;245(2):96–108. DOI: 10.1177/1535370219898141